
Takahiro Miyazu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12057590/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis. Scientific Reports, 2021, 11, 12431. | 3.3 | 15 |
| 2 | Photodynamic Therapy Using Talaporfin Sodium for Local Failure after Chemoradiotherapy or Radiotherapy for Esophageal Cancer: A Single Center Experience. Journal of Clinical Medicine, 2020, 9, 1509. | 2.4 | 13 |
| 3 | Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis. BMC Gastroenterology, 2020, 20, 114. | 2.0 | 10 |
| 4 | Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker. International Journal of Colorectal Disease, 2020, 35, 1729-1739. | 2.2 | 9 |
| 5 | Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis. Digestive Diseases and Sciences, 2022, 67, 3984-3992. | 2.3 | 7 |
| 6 | Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission. Clinical and Translational Gastroenterology, 2020, 11, e00289. | 2.5 | 7 |
| 7 | Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation. Scientific Reports, 2020, 10, 21353. | 3.3 | 6 |
| 8 | Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease. PLoS ONE, 2021, 16, e0254548. | 2.5 | 5 |
| 9 | Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis. Scientific Reports, 2021, 11, 16205. | 3.3 | 5 |
| 10 | Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse. International Journal of Colorectal Disease, 2021, 36, 2661-2670. | 2.2 | 5 |
| 11 | Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation. Inflammatory Bowel Diseases, 2021, 27, e3-e4. | 1.9 | 4 |
| 12 | Tuberous sclerosis patient with neuroendocrine carcinoma of the esophagogastric junction: A case report. World Journal of Gastroenterology, 2020, 26, 7263-7271. | 3.3 | 4 |
| 13 | Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis. Scientific Reports, 2021, 11, 13676. | 3.3 | 3 |
| 14 | A Rare Lesion at the lleostomy Site of a Patient With Intestinal Behçet's Disease. Gastroenterology, 2020, 159, e14-e15. | 1.3 | 2 |
| 15 | Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy. Gastroenterology Report, 2022, 10, . | 1.3 | 1 |
| 16 | Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease. PLoS ONE, 2021, 16, e0250658. | 2.5 | 0 |
| 17 | Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis. Immuno, 2021, 1, 360-368. | 1.5 | 0 |